LIXT
Lixte Biotechnology Holdings, Inc.
Price Chart
Latest Quote
$6.85
-0.02 (-0.29%)
Current Price
| Previous Close | $6.87 |
| Open | $6.94 |
| Day High | $6.99 |
| Day Low | $6.55 |
| Volume | 41,941 |
Stock Information
| Shares Outstanding | 17.39M |
| Total Debt | $1.06M |
| Cash Equivalents | $3.25M |
| Net Income | $-7.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $119.10M |
| EPS (TTM) | $-1.15 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $84.11M |
| Income | $-7.31M |
| Book/sh | $0.68 |
| Cash/sh | $0.19 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 2.65 |
| Current Ratio | 2.78 |
| Debt/Eq | 11.52 |
Returns & Margins
| ROA | -64.50% |
| ROE | -140.99% |
Ownership
| Insider Ownership | 8.68% |
| Institutional Ownership | 5.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 10.03 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $6.89 |
| SMA50 | $5.42 |
| SMA200 | $4.26 |
| RSI | 48.21 |
| ATR | 0.7736 |
| Shares Float | 10.99M |
| Short Float | 2.02% |
| Short Ratio | 2.55 |
| Volatility | 1.28 |
| Rel Volume | 0.11 |
Performance History
| Week | -1.58% |
| Month | +21.24% |
| Quarter | +129.10% |
| 6 Months | +64.27% |
| YTD | +78.39% |
| Year | +687.36% |
| 3 Years | +21.67% |
| 5 Years | -76.94% |
| 10 Years | -42.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $6.85 | 41,941 |
| 2026-06-24 | $6.87 | 290,000 |
| 2026-06-23 | $7.30 | 472,100 |
| 2026-06-22 | $7.48 | 511,300 |
| 2026-06-18 | $7.61 | 1,007,700 |
| 2026-06-17 | $6.96 | 508,200 |
| 2026-06-16 | $6.88 | 774,800 |
| 2026-06-15 | $6.72 | 348,800 |
| 2026-06-12 | $6.19 | 871,800 |
| 2026-06-11 | $7.25 | 442,100 |
| 2026-06-10 | $6.89 | 189,800 |
| 2026-06-09 | $6.87 | 254,600 |
| 2026-06-08 | $6.65 | 419,200 |
| 2026-06-05 | $7.00 | 149,800 |
| 2026-06-04 | $7.00 | 183,300 |
| 2026-06-03 | $6.71 | 244,300 |
| 2026-06-02 | $7.04 | 304,000 |
| 2026-06-01 | $7.21 | 817,400 |
| 2026-05-29 | $6.25 | 40,300 |
| 2026-05-28 | $5.99 | 85,700 |
| 2026-05-27 | $6.42 | 236,600 |
| 2026-05-26 | $5.65 | 153,400 |
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $9,158 | $16,821 | $16,233 | $8,875 |
| Total Expenses | $5,107,621 | $3,572,789 | $5,090,236 | $6,311,481 |
| Other Income Expense | $-900,129 | $-3,403 | $1,954 | $-3,374 |
| Other Non Operating Income Expenses | $3,740 | - | - | - |
| Net Non Operating Interest Income Expense | $-1,770 | $-9,773 | $1,253 | $2,320 |
| Interest Expense Non Operating | $9,158 | $16,821 | $16,233 | $8,875 |
| Operating Expense | $5,107,621 | $3,572,789 | $5,090,236 | $6,311,481 |
| General And Administrative Expense | $4,852,702 | $2,846,557 | $4,192,136 | $4,962,212 |
| Other Operating Expenses | - | - | - | $1,146,289 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Net Interest Income | $-1,770 | $-9,773 | $1,253 | $2,320 |
| Interest Income | $7,388 | $7,048 | $17,486 | $11,195 |
| Normalized Income | $-5,105,651 | $-3,582,562 | $-5,088,983 | $-6,309,161 |
| Net Income From Continuing And Discontinued Operation | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Total Operating Income As Reported | $-5,107,621 | $-3,572,789 | $-5,090,236 | $-6,311,481 |
| Net Income Common Stockholders | $-6,078,593 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Net Income | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Net Income Including Noncontrolling Interests | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Net Income Continuous Operations | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Pretax Income | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Interest Income Non Operating | $7,388 | $7,048 | $17,486 | $11,195 |
| Operating Income | $-5,107,621 | $-3,572,789 | $-5,090,236 | $-6,311,481 |
| Per Share | ||||
| Diluted EPS | $-1.26 | $-1.59 | $-2.66 | $-3.99 |
| Basic EPS | $-1.26 | $-1.59 | $-2.66 | $-3.99 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,096,493 | $-3,565,741 | $-5,072,750 | $-6,300,286 |
| Total Unusual Items | $-903,869 | $-3,403 | $1,954 | $-3,374 |
| Total Unusual Items Excluding Goodwill | $-903,869 | $-3,403 | $1,954 | $-3,374 |
| EBITDA (Bullshit earnings) | $-6,000,362 | $-3,569,144 | $-5,070,796 | $-6,303,660 |
| EBIT | $-6,000,362 | $-3,569,144 | $-5,070,796 | $-6,303,660 |
| Diluted Average Shares | $4,840,731 | $2,249,290 | $1,915,838 | $1,582,029 |
| Basic Average Shares | $4,840,731 | $2,249,290 | $1,915,838 | $1,582,029 |
| Diluted NI Availto Com Stockholders | $-6,078,593 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Preferred Stock Dividends | $69,073 | - | - | - |
| Minority Interests | $0 | $0 | - | - |
| Gain On Sale Of Security | $-903,869 | $-3,403 | $1,954 | $-3,374 |
| Research And Development | $254,919 | $726,232 | $898,100 | $1,349,269 |
| Selling General And Administration | $4,852,702 | $2,846,557 | $4,192,136 | $4,962,212 |
| Other Gand A | $2,455,042 | $1,240,567 | $2,030,980 | $2,414,597 |
| Insurance And Claims | $257,478 | $434,444 | $442,976 | - |
| Salaries And Wages | $2,140,182 | $1,171,546 | $1,718,180 | $2,547,615 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $9,664,059 | $827,219 | $3,994,762 | $5,165,227 |
| Total Assets | $12,733,621 | $1,145,503 | $4,308,620 | $5,560,983 |
| Total Non Current Assets | $7,555,242 | $0 | $0 | $0 |
| Current Assets | $5,178,379 | $1,145,503 | $4,308,620 | $5,560,983 |
| Prepaid Assets | $71,507 | $106,551 | $105,132 | $207,591 |
| Cash Cash Equivalents And Short Term Investments | $5,106,872 | $1,038,952 | $4,203,488 | $5,353,392 |
| Cash And Cash Equivalents | $5,106,872 | $1,038,952 | $4,203,488 | $5,353,392 |
| Cash Financial | $5,106,872 | $1,038,952 | $4,203,488 | $5,353,392 |
| Other Current Assets | - | - | - | $10,380 |
| Debt | ||||
| Total Debt | $664,491 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $664,491 | - | - | - |
| Current Debt | $69,073 | - | - | - |
| Other Current Borrowings | $69,073 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,772,070 | $318,284 | $313,858 | $395,756 |
| Total Non Current Liabilities Net Minority Interest | $438,959 | $0 | $0 | $0 |
| Current Liabilities | $1,333,111 | $318,284 | $313,858 | $395,756 |
| Current Deferred Liabilities | $232,138 | $235,078 | $157,100 | $165,022 |
| Payables And Accrued Expenses | $436,482 | $83,206 | $156,758 | $230,734 |
| Payables | - | - | $156,758 | $230,734 |
| Accounts Payable | - | - | $120,508 | $183,752 |
| Equity | ||||
| Common Stock Equity | $7,932,490 | $-2,672,781 | $494,762 | $1,665,227 |
| Preferred Stock Equity | $1,731,569 | $3,500,000 | $3,500,000 | $3,500,000 |
| Total Equity Gross Minority Interest | $10,961,551 | $827,219 | $3,994,762 | $5,165,227 |
| Stockholders Equity | $9,664,059 | $827,219 | $3,994,762 | $5,165,227 |
| Retained Earnings | $-58,077,213 | $-52,067,693 | $-48,481,728 | $-43,394,699 |
| Other | ||||
| Ordinary Shares Number | $8,790,102 | $2,249,290 | $2,249,290 | $1,664,659 |
| Share Issued | $8,790,102 | $2,249,290 | $2,249,290 | $1,664,659 |
| Tangible Book Value | $7,932,490 | $-2,672,781 | $494,762 | $1,665,227 |
| Invested Capital | $8,001,563 | $-2,672,781 | $494,762 | $1,665,227 |
| Working Capital | $3,845,268 | $827,219 | $3,994,762 | $5,165,227 |
| Capital Lease Obligations | $595,418 | $0 | - | - |
| Total Capitalization | $9,664,059 | $827,219 | $3,994,762 | $5,165,227 |
| Minority Interest | $1,297,492 | $0 | - | - |
| Additional Paid In Capital | $66,008,824 | $49,394,687 | $48,976,265 | $45,059,760 |
| Capital Stock | $1,732,448 | $3,500,225 | $3,500,225 | $3,500,166 |
| Common Stock | $879 | $225 | $225 | $166 |
| Preferred Stock | $1,731,569 | $3,500,000 | $3,500,000 | $3,500,000 |
| Current Deferred Revenue | $232,138 | $235,078 | $157,100 | $165,022 |
| Current Capital Lease Obligation | $595,418 | $0 | - | - |
| Net PPE | $7,555,242 | $0 | - | - |
| Gross PPE | $7,555,242 | $0 | - | - |
| Other Properties | $7,555,242 | - | - | - |
| Dueto Related Parties Current | - | - | $36,250 | $46,982 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,070,618 | $-3,164,536 | $-4,293,265 | $-4,611,737 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,070,618 | $-3,164,536 | $-4,293,265 | $-4,611,737 |
| Cash Flow From Continuing Operating Activities | $-3,070,618 | $-3,164,536 | $-4,293,265 | $-4,611,737 |
| Operating Gains Losses | $904,394 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-3,172,462 | $0 | - | - |
| Cash Flow From Continuing Investing Activities | $-3,172,462 | $0 | - | - |
| Net Other Investing Changes | $-95,102 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,265,199 | $0 | $3,137,039 | $5,141,384 |
| Financing Cash Flow | $10,311,000 | $0 | $3,143,361 | $5,141,384 |
| Cash Flow From Continuing Financing Activities | $10,311,000 | $0 | $3,143,361 | $5,141,384 |
| Net Common Stock Issuance | $10,265,199 | $0 | $3,137,039 | $5,141,384 |
| Common Stock Issuance | $10,265,199 | $0 | $3,137,039 | $5,141,384 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $9,158 | $16,821 | $16,233 | $8,875 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $5,106,872 | $1,038,952 | $4,203,488 | $5,353,392 |
| Beginning Cash Position | $1,038,952 | $4,203,488 | $5,353,392 | $4,823,745 |
| Changes In Cash | $4,067,920 | $-3,164,536 | $-1,149,904 | $529,647 |
| Proceeds From Stock Option Exercised | $45,801 | $0 | $6,322 | $0 |
| Net Investment Purchase And Sale | $-3,077,360 | $0 | - | - |
| Purchase Of Investment | $-3,077,360 | $0 | - | - |
| Change In Working Capital | $412,880 | $3,007 | $20,561 | $154,758 |
| Change In Other Working Capital | $-2,940 | $77,978 | $-7,922 | $88,061 |
| Change In Payables And Accrued Expense | $380,776 | $-73,552 | $-73,976 | $2,318 |
| Change In Prepaid Assets | $35,044 | $-1,419 | $102,459 | $64,379 |
| Other Non Cash Items | $61,695 | - | - | - |
| Stock Based Compensation | $1,559,933 | $418,422 | $773,203 | $1,546,040 |
| Gain Loss On Investment Securities | $904,394 | - | - | - |
| Net Income From Continuing Operations | $-6,009,520 | $-3,585,965 | $-5,087,029 | $-6,312,535 |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
| Change In Receivables | - | - | - | - |
Fetched: 2026-06-24